

Clarification of ASX Release dated 14 August 2020

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), attaches a revised announcement to clarify it has received acceptance of a patent application in China for its pain assessment invention (Chinese Patent Application No. 201580044679.7).

This release has been authorized for release by CEO Philip Daffas.

For more information:

Ian Hobson
Company Secretary, PainChek
ianhobson@bigpond.com
+61 8 9388 8290

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person’s face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

Acceptance of patent application in China

Approval provides protection in large international market

HIGHLIGHTS

- Acceptance of application by Chinese Patent Office follows patents granted in Australia, Japan and the US
- Patent will provide PainChek® with intellectual property protection in China as it looks to grow its footprint into larger international markets
- It is estimated that in 2020 the number of people with dementia in China will be 16.93 million, increasing to 35.98 million by 2050¹
- PainChek® is awaiting patent approvals in other regions including Europe and the UK
- PainChek® is used in more than 700 aged care facilities globally, with client numbers up 500% in FY2020

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smartphone-based pain assessment and monitoring application, is pleased to announce it has received acceptance of a patent application in China for its pain assessment invention (Chinese Patent Application No. 201580044679.7).

The Company received notification that the Chinese Patent Office had accepted its application, following on from the receipt of similar protection for its intellectual property (IP) in Australia, the US and Japan. Subject to payment of fees and formalities, the Chinese Patent office will grant a patent, which will provide PainChek® with exclusive rights to making, using, selling or importing the invention in China until 18 August 2035.

PainChek® is the world’s first smartphone pain assessment and monitoring device. The app automatically assesses pain via artificial intelligence and facial recognition technology. Research² shows it is already driving higher quality aged care and improved pain management in residential settings around Australia.

PainChek CEO Philip Daffas said:

“We are really pleased to receive this confirmation in China as this represents a new, large market opportunity for PainChek. Having this IP protection in China is an important part of our strategy as we look to grow in overseas markets.”

The Company has also applied for patents in the United Kingdom and Europe and is awaiting acceptance of these.

PainChek® is used in more than 700 aged care facilities around the world, with Australia being its largest market to date. Its total client numbers have grown more than 500% in the past financial year.

¹ Wang, Y.Q.; Jia, R.X.; Liang, J.H.; Li, J.; Qian, S.; Li, J.Y.; Xu, Y. Dementia in China (2015–2050) estimated using the 1% population sampling survey in 2015. *Geriatr. Gerontol. Int.* 2019, 19, 1096–1100.

This release has been authorized for release by CEO Philip Daffas.

For more information:

Ian Hobson
Company Secretary, PainChek
ianhobson@bigpond.com
+61 8 9388 8290

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com